Iribarren et al., “Metabolic Syndrome and Early-Onset Coronary Artery Disease,” J.Takeno et al., “Impact of Metabolic Syndrome on the Long-Term Survival of Patients With Acute Myocardial Infarction,” Circ.Levantesi et al., “Metabolic Syndrome and Risk of Cardiovascular Events After Myocardial Infarction,” J.Chrousos, “Metabolic syndrome: definitions and controversies,” BMC Med., vol. Kloner, “Management of No-Reflow Phenomenon in the Catheterization Laboratory,” JACC Cardiovasc. Amano et al., “Plaque Composition and No-Reflow Phenomenon During Percutaneous Coronary Intervention of Low-Echoic Structures in Grayscale Intravascular Ultrasound,” Int.Germain, “The no-reflow phenomenon: State of the art,” Arch. Kloner, “No-reflow phenomenon following percutaneous coronary intervention for acute myocardial infarction: Incidence, outcome, and effect of pharmacologic therapy,” J. Jennings, “The ‘ No-Reflow ’ Phenomenon after Temporary Coronary Occlusion in the Dog Find the latest version : The " No-Reflow " Phenomenon after Temporary Coronary Occlusion in the Dog,” vol. Ibanez et al., “2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation,” Eur.There were significant negative correlations between the MS score and both the post-intervention TIMI flow grade and MBG ( P<0.001 for both).Ĭonclusions: MS plays an important role in the development of no-reflow in STEMI patients treated with PPCI with significant negative correlations between the MS score and both the post-intervention TIMI flow grade and MBG. The fasting blood glucose level and the time from symptom onset to wire crossing were independent predictors of the no-reflow phenomenon (OR, 1.225 95% CI, 1.105 to 2.854 P<0.001) and (OR, 1.049 95% CI, 1.026 to 1.073 P<0.001). The patients with no-reflow had a higher prevalence of MS, a higher level of triglycerides, a lower level of high-density lipoprotein, and a higher fasting blood glucose level. Results: Totally, 26 patients (26%) developed no-reflow. The MS score was defined as the number of MS components present. MS was defined based on the National Cholesterol Education Program criteria. Angiographic no-reflow was defined as a thrombolysis in myocardial infarction (TIMI) risk score of below 3 or a TIMI risk score of 3 with a myocardial blushing grade (MBG) of 0 to 1 in the absence of mechanical complications. Methods: We prospectively included 100 patients with STEMI treated with PPCI. We aimed to examine the association between angiographic outcomes including angiographic no-reflow and MS. Background: The relationship between metabolic syndrome (MS) and the MS score and the angiographic outcome of primary percutaneous coronary intervention (PPCI) for ST-segment-elevation myocardial infarction (STEMI) is still unclear.
0 Comments
Leave a Reply. |
AuthorWrite something about yourself. No need to be fancy, just an overview. ArchivesCategories |